In my last post, I mentioned that Synta had shown a doubling of progression-free survival in their STA-4783 phase 2b trial on melanomas. I thought I’d take a break from analyzing Synta and figure out if progression-free survival is really the best endpoint for them to be using (and is a doubling really […]

Filed under: Evaluating Clinical Trials | 12 Comments »

I’ve read quite a few interesting posts about clinical trials in the last few days and I thought I’d share them with you.

Eye on FDA has a good post about FDA approval letters.  Mark points out that companies have all the say on how much of the content of the letter gets released and highlights […]

Filed under: Evaluating Clinical Trials | 3 Comments »